文献速递类风湿关节炎

整合血清蛋白质组学与自身抗体分析揭示类风湿关节炎生物制剂减量期间预测复发的生物标志物特征

Integrated serum proteomics and autoantibody analyses reveal a biomarker signature predictive of flare during biologic tapering in rheumatoid arthritis.
PubMed 文献 · RMD Open · 2026-09-23

本研究基于OPTIBIO试验基线血清,采用发现集(n=44)质谱探索和全队列(n=194)ELISA验证的两阶段设计,识别预测RA生物制剂减量期间复发的循环蛋白标志物。VSIG4和抗IFNγ自身抗体独立关联复发风险,联合临床模型AUC从0.666提升至0.760,在长期缓解亚组中AUC达0.839。结论提示生物标志物指导的风险分层有潜力,但需外部验证。

要点

  • VSIG4与抗IFNγ自身抗体独立预测RA生物制剂减量后复发。
  • 联合VSIG4、抗IFNγ和DAS28-CRP的模型AUC 0.760优于临床模型0.666。
  • 长期缓解亚组预测性能更佳(AUC 0.839),但需外部验证。

核心结论

  • VSIG4和抗IFNγ自身抗体与RA生物制剂减量期间复发独立相关,联合临床模型可改善预测区分度。

研究设计与样本

  • 基于OPTIBIO临床试验中持续缓解RA患者的基线血清,采用两阶段设计:发现集n=44(优化组与对照组各22例)行质谱探索,全队列n=194行ELISA验证及抗细胞因子自身抗体谱分析。

主要发现

  • 随访期间优化组复发率46.4%,对照组30.9%。
  • 发现集优化组中87种蛋白在复发与持续缓解患者间差异丰富。
  • VSIG4被验证为与复发风险增加相关的生物标志物,抗IFNγ自身抗体亦独立关联复发。
  • 联合VSIG4、抗IFNγ和DAS28-CRP的模型AUC 0.760,优于临床模型AUC 0.666,决策曲线分析显示更高敏感性和临床效用。
  • 长期缓解亚组探索性分析中预测性能进一步提升(AUC 0.839)。

关键数值与推荐

  • 主要结局为随访期间疾病复发。
  • 联合模型较临床模型AUC提高(0.760 vs 0.666)。
  • 长期缓解亚组AUC 0.839。

临床怎么用

  • VSIG4和抗IFNγ自身抗体联合DAS28-CRP可能辅助识别生物制剂减量后高复发风险的RA患者,但临床实施前需外部验证。

局限性

  • 需外部验证后方可临床实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reliable biomarkers predicting which patients with rheumatoid arthritis (RA) can safely undergo biologic tapering are currently lacking. This study aimed to identify circulating protein biomarkers predictive of flare during biologic disease-modifying anti-rheumatic drug tapering in RA. METHODS: Baseline serum samples from patients with RA in sustained remission enrolled in the Biologic Optimisation (OPTIBIO) clinical trial were analysed using a two-stage design comprising an exploratory mass spectrometry in a discovery sample subset (n=44, 22 in the optimisation arm and 22 in the control arm), followed by ELISA validation of selected protein biomarkers and anti-cytokine autoantibody profiling in the full cohort (n=194). The primary outcome was a disease flare during follow-up. RESULTS: During follow-up, disease flare occurred in 46.4% of patients in the optimisation arm and 30.9% in the control arm. Within the discovery subset of the optimisation arm, 87 proteins were differentially abundant between patients who flared and those who remained in remission. V-set immunoglobulin-domain-containing 4 (VSIG4) was validated as a biomarker associated with increased flare risk while anti-interferon-γ (anti-IFNγ) autoantibodies were also independently associated with flare. A combined model integrating VSIG4, anti-IFNγ and Disease Activity Score 28-joint count using C reactive protein improved discrimination compared with the clinical model alone (area under the curve (AUC) 0.760 vs 0.666) and showed higher sensitivity and greater potential clinical utility in decision curve analysis. In a secondary exploratory subgroup of patients with prolonged remission, predictive performance further improved (AUC 0.839). CONCLUSION: These findings identify a promising protein biomarker signature associated with flare during biologic tapering in RA, supporting biomarker-guided risk stratification in treatment optimisation strategies. External validation is required before clinical implementation.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Blanco FJ, Quaranta P, Domínguez-Guerrero P, et al. Integrated serum proteomics and autoantibody analyses reveal a biomarker signature predictive of flare during biologic tapering in rheumatoid arthritis. RMD Open. 2026. PMID: 42778334. doi:10.1136/rmdopen-2026-007198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。